SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
|
Design
|
Interim-analysis of a prospective, randomized, phase II, double-blind, placebo-controlled, single-dose study
N=452
|
Objective
|
To evaluate the efficacy and safety of LY-CoV555 (bamlanivimab) in patients with recently diagnosed mild or moderate COVID-19 in the outpatient setting
|
Study Groups
|
LY-CoV555 (n=309)
- 700 mg (n=101)
- 2,800 mg (n=107)
- 7,000 mg (n=101)
Placebo (n=143)
|
Methods
|
Inclusion criteria: ≥18 years of age, not hospitalized, had one or more mild or moderate COVID-19 symptoms (fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with exertion), a nasopharyngeal sample for positive SARS-CoV-2 viral infection determination ≤3 days before the start of the infusion, men or non-pregnant women agreeing to use contraception
Exclusion criteria: SpO2 ≤93%, PaO2/FiO2 <300, respiratory rate ≥30 per minute, heart rate ≥125 bpm, required mechanical ventilation or anticipated impending need for mechanical ventilation, hemodynamic unstable, suspected or proven serious infection of any kind, unstable comorbidities, history of a positive SARS-CoV-2 serology test, history of positive SARS-CoV-2 test, previously received an investigational intervention for SARS-CoV-2, history of convalescent COVID-19 plasma treatment, breastfeeding
Patients were randomized to receive a single intravenous infusion of neutralizing antibody bamlanivimab in one of three doses (700 mg, 2,800 mg, or 7,000 mg) or placebo. Patients were defined to have moderate symptoms if they presented with shortness of breath OR respiratory rate ≥20 breaths/min plus pulse ≥95 beats/min. All other symptomatic patients were deemed to have mild severity.
|
Duration
|
Interim analysis follow-up: 29 days
Trial protocol follow-up: 85 days; assessment at day 29; follow-up at day 60 and day 85
|
Outcome Measures
|
Interim analysis primary outcome: changes from baseline in the viral load at day 11
Interim analysis secondary outcomes: changes from baseline in viral load at day 3 and at day 7; incidence of hospitalization
|
Baseline Characteristics
|
|
Bamlanivimab (n=309)
|
Placebo (n=143)
|
|
Age, years (range)
>65 years
|
45 (18-86)
33 (10.7%)
|
46 (18-77)
20 (14.0%)
|
|
Female
|
171 (55.3%) |
78 (54.5%) |
|
Race
White
Hispanic/Latino
Black
|
269/305 (88.2%)
135/309 (43.7%)
22/305 (7.2%)
|
120/138 (87.0%)
63/143 (44.1%)
7/138 (5.1%)
|
|
BMI, kg/m2
≥30 to <40
≥40
|
29.4
112/304 (36.8%)
24/304 (7.9%)
|
29.1
56/139 (40.3%)
9/139 (6.5%)
|
|
Risk factors for severe Covid-19
|
215 (69.6%)
|
95 (66.4%)
|
|
Covid-19 status
Mild
Moderate
|
232 (75.1%)
77 (24.9%)
|
113 (79.0%)
30 (21.0%)
|
|
Median days since onset of symptoms
|
4
|
4
|
|
Mean viral load, Ct value
|
23.9
|
23.8
|
|
Results
|
Endpoint
|
Bamlanivimab (n=309)
|
Placebo (n=143)
|
Difference (95%CI)
|
Mean change from baseline in viral load at day 11
|
700 mg (n=101): -3.67
2,800 mg (n=107): -4.00
7,000 mg (n=101): -3.38
|
-3.47 |
-0.20 (-0.66 to 0.25)
-0.53 (-0.98 to -0.08)
+0.09 (-0.37 to 0.55)
|
Mean change from baseline in viral load at day 7
|
700 mg (n=101): -2.82
2,800 mg (n=107): -3.01
7,000 mg (n=101): -2.85
|
-2.56 |
-0.42 (-0.89 to 0.06)
-0.64 (-1.11 to -0.17)
-0.42 (-0.90 to 0.06)
|
Mean change from baseline in viral load at day 3
|
700 mg (n=101): -1.27
2,800 mg (n=107): -1.50
7,000 mg (n=101): -1.27
|
-0.85 |
-0.25 (-0.73 to 0.23)
-0.45 (-0.92 to 0.03)
-0.28 (-0.77 to 0.20)
|
Hospitalization related to COVID-19 by day 29
|
5 (1.6%)
700 mg (n=101): 1 (1.0%)
2,800 mg (n=107): 2 (2.0%)
7,000 mg (n=101): 2 (2.0%)
|
9 (6.3%) |
--- |
Patients with a higher viral load on day 7 had a higher rate of hospitalization than those with a better clearance of viral RNA on day 7, a finding that is consistent with previous studies suggesting that delayed viral clearance is associated with more severe disease.
|
Adverse Events
|
Common Adverse Events: Nausea (3.9%), diarrhea (3.2%), dizziness (3.2%), headache (1.6%), pruritus (1.6%), vomiting (1.6%), chills (1.3%), pyrexia (1.3%), chest discomfort (1.0%), fatigue (1.0%), hypertension (1.0%), lipase increased (1.0%), thrombocytosis (1.0%)
|
Serious Adverse Events: 0%
|
Percentage that Discontinued due to Adverse Events: 0%
|
Study Author Conclusions
|
The safety profile of patients who received bamlanivimab was similar to that of placebo-treated patients. Although the differences in the effects of the three doses of bamlanivimab were not clear, the 2,800 mg dose was the only one to show evidence of accelerated viral clearance. Patients receiving bamlanivimab also had fewer hospitalizations and a lower symptom burden than those who received placebo, with the most pronounced effects observed in high-risk cohorts.
|
InpharmD Researcher Critique
|
Strengths of this study include the placebo-controlled and double-blinded design. Limitations include the fact that this is an interim analysis and the primary outcome is a surrogate endpoint; however, the key secondary endpoint of hospitalization favorably associated with the lower viral load. Additionally, viral samples were nasopharyngeal instead of bronchial; however, it can be argued that nasopharyngeal swabs may be appropriate in these patients.
|